Visual Cortex Disease

Categories: Eye diseases

Aliases & Classifications for Visual Cortex Disease

MalaCards integrated aliases for Visual Cortex Disease:

Name: Visual Cortex Disease 12 14
Visual Cortex Dysfunction 12
Visual Cortex Disorder 69


External Ids:

Disease Ontology 12 DOID:5691
ICD10 33 H47.6
ICD9CM 35 377.7
NCIt 47 C35275
UMLS 69 C0234398

Summaries for Visual Cortex Disease

MalaCards based summary : Visual Cortex Disease, also known as visual cortex dysfunction, is related to prostate carcinoma in situ and penis sarcoma. An important gene associated with Visual Cortex Disease is IER3IP1 (Immediate Early Response 3 Interacting Protein 1). The drugs Betamethasone and Dexamethasone have been mentioned in the context of this disorder. Affiliated tissues include cortex, brain and eye, and related phenotypes are pigmentation and vision/eye

Related Diseases for Visual Cortex Disease

Graphical network of the top 20 diseases related to Visual Cortex Disease:

Diseases related to Visual Cortex Disease

Symptoms & Phenotypes for Visual Cortex Disease

MGI Mouse Phenotypes related to Visual Cortex Disease:

id Description MGI Source Accession Score Top Affiliating Genes
1 pigmentation MP:0001186 9.13 CLN8 DOCK7 MFSD8
2 vision/eye MP:0005391 9.02 DOCK7 MFSD8 PRNP CLN6 CLN8

Drugs & Therapeutics for Visual Cortex Disease

Drugs for Visual Cortex Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 160)
id Name Status Phase Clinical Trials Cas Number PubChem Id
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3 50-02-2 5743
3 Homatropine Approved Phase 4 87-00-3
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946
Choline Approved, Nutraceutical Phase 4 62-49-7 305
Imidacloprid Vet_approved Phase 4 105827-78-9 86418
7 Autonomic Agents Phase 4,Phase 3,Phase 1,Phase 2
8 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1,Phase 2
9 Respiratory System Agents Phase 4,Phase 3,Phase 1,Phase 2
10 Cytidine Diphosphate Choline Phase 4
11 Nootropic Agents Phase 4
12 Anti-Asthmatic Agents Phase 4,Phase 3
13 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2
14 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2
15 Antiemetics Phase 4,Phase 3
16 Anti-Infective Agents Phase 4,Phase 3,Phase 2
17 Anti-Inflammatory Agents Phase 4,Phase 3
18 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2
19 BB 1101 Phase 4,Phase 3
20 Betamethasone benzoate Phase 4
21 Betamethasone sodium phosphate Phase 4
22 Betamethasone Valerate Phase 4 2152-44-5
23 Betamethasone-17,21-dipropionate Phase 4
24 Dexamethasone acetate Phase 4,Phase 3 1177-87-3
25 Gastrointestinal Agents Phase 4,Phase 3
26 glucocorticoids Phase 4,Phase 3
27 HIV Protease Inhibitors Phase 4,Phase 3
28 Hormone Antagonists Phase 4,Phase 3,Phase 2
29 Hormones Phase 4,Phase 3,Phase 2
30 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2
31 Norgestimate, ethinyl estradiol drug combination Phase 4
32 Parasympatholytics Phase 4
protease inhibitors Phase 4,Phase 3
34 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2
Ciclesonide Approved, Investigational Phase 3 126544-47-6, 141845-82-1 444033
Doxorubicin Approved, Investigational Phase 3,Phase 2 23214-92-8 31703
Dopamine Approved Phase 3,Phase 2 51-61-6, 62-31-7 681
Asparaginase Approved Phase 3 9015-68-3
Clofarabine Approved, Investigational Phase 3 123318-82-1 119182
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
Cytarabine Approved, Investigational Phase 3 147-94-4 6253
Dasatinib Approved, Investigational Phase 3 302962-49-8 3062316
Daunorubicin Approved Phase 3 20830-81-3 30323
Etoposide Approved Phase 3 33419-42-0 36462
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
Pegaspargase Approved, Investigational Phase 3 130167-69-0
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
Thioguanine Approved Phase 3 154-42-7 2723601

Interventional clinical trials:

(show top 50) (show all 167)

id Name Status NCT ID Phase Drugs
1 Citicoline Effect on Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) Completed NCT03046693 Phase 4 Group A Citicoline 1000 mg oral tablet;Group B placebo oral tablet
2 Comparing SD-tVEP and PERG Tests Between Patients With Glaucoma, Patients With High Eye Pressure and "Normal" Patients Completed NCT02604953 Phase 4
3 Intraoperative Dexamethasone Implant Improves Outcome of Cataract Surgery With Diabetic Macular Edema Completed NCT01546402 Phase 4 Dexamethasone Drug delivery system (Ozurdex)
4 Perioperative Mirror Therapy and Phantom Limb Pain Recruiting NCT02383979 Phase 4
5 Influence of Transcranial Direct Current Stimulation of the Primary Motor Cortex on Pain Sensation in Patients Suffering From Fibromyalgia Syndrome Terminated NCT01261650 Phase 4
6 Anodal Transcranial Direct Current Stimulation of the Visual Cortex Versus Sham Stimulation in the Episodic Migraine Unknown status NCT02122757 Phase 3
7 Using Repetitive Transcranial Magnetic Stimulation (rTMS) in the Rehabilitation of Chronic Spatial Neglect After Stroke Unknown status NCT01000103 Phase 3
8 RCT Versus Placebo of rTMSQP Over Visual Cortex for the Prevention of Chronic Migraine Completed NCT02122744 Phase 3
9 Cathodal tDCS in Chronic Migraine: Neurophysiological Study and Pilot Therapeutic Trial Completed NCT02122237 Phase 3
10 Paraorbital-Occipital Electric Stimulation in Patients With Optic Neuropathy (BCT_optnerve) Completed NCT01282827 Phase 2, Phase 3
11 Effects Of Ciclesonide And Beclomethasone On Lens Opacification In Adult Subjects With Moderate To Severe Persistent Asthma Completed NCT00254956 Phase 3 ciclesonide (XRP1526)
12 Autopsy Follow-up of Subjects Previously Imaged With Florbetapir F 18 (18F-AV-45) PET in Trial 18F-AV-45-A07 Completed NCT01447719 Phase 3 florbetapir F 18
13 ADHD Electrophysiological Subtypes and Implications in Transcranial Direct-current Stimulation Completed NCT01649232 Phase 3
14 Study of Genetic Alzheimer's Disease Mutation Carriers in Preclinical Stages of the Disease 18F-Florbetaben Positron Emission Tomography Study Recruiting NCT02362880 Phase 2, Phase 3
15 Neurostimulation and Cognitive Intervention in Alzheimer's Disease Recruiting NCT02772185 Phase 2, Phase 3
16 Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia Active, not recruiting NCT00549848 Phase 3 Prednisone, Vincristine, Daunorubicin, PEG-L-asparaginase, Erwinia L-asparaginase, Doxorubicin, Cyclophosphamide, Cytarabine, Thioguanine;Clofarabine, Methotrexate, Mercaptopurine, Dexamethasone, Etoposide, Dasatinib
17 Brexpiprazole (OPC 34712) Trial in the Treatment of Adults With Major Depressive Disorder and Irritability Withdrawn NCT02212613 Phase 3 Brexpiprazole
18 Does tDCS is Effective in the Prophylactic Treatment of Migraine Unknown status NCT01886274 Phase 2
19 Effects of Magnetic Therapy and Seawater Combined in Decreasing Intraocular Presion. Unknown status NCT02300818 Phase 1, Phase 2 Seawater eyedrops
20 Association of Functional Changes in the Brain and the Perception of Pain in Patients With Chronic Inflammatory Bowel Diseases (IBD) Unknown status NCT02433470 Phase 2
21 Evaluation of the Effect of Repetitive Transcranial Magnetic Stimulation in Pain Perception in Parkinson's Disease Completed NCT01275573 Phase 2
22 Trial of Alternating Current Stimulation in Optic Neuropathy Completed NCT01270126 Phase 2
23 Repetitive Transcranial Magnetic Stimulation With Or Without Traumatic Stimuli in Post Traumatic Stress Disorder (PTSD) Completed NCT01196624 Phase 2
24 Combined tDCS and Vision Restoration Training in Subacute Stroke Rehabilitation: A Pilot Study Completed NCT02935413 Phase 1, Phase 2
25 Combined tDCS and Vision Restoration Training in Post-acute Stroke: an Exploratory Efficacy and Safety Study Completed NCT02703870 Phase 1, Phase 2
26 Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment Completed NCT00091182 Phase 2 oxaliplatin
27 Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors Completed NCT00002608 Phase 2 cisplatin;doxorubicin hydrochloride;tamoxifen citrate
28 Safety and Effectiveness of Repetitive Transcranial Magnetic Stimulation in the Treatment of Tinnitus Completed NCT00518024 Phase 2
29 Study Evaluating the Safety,Tolerability and Efficacy of PF-04360365 in Adults With Probable Cerebral Amyloid Angiopathy Completed NCT01821118 Phase 2
30 The Efficacy of Viburnum Opulus 3X in the Treatment of Primary Dysmenorrhea Completed NCT02467543 Phase 2
31 tDCS for the Treatment of Migraine Recruiting NCT02562196 Phase 2
32 Optimized tDCS for the Treatment of Migraine Recruiting NCT02562222 Phase 2
33 Assessment of Optic Nerve Radiation in Patients With Glaucoma and Ocular Hypertension by 7 Tesla Diffusion Tensor Imaging Recruiting NCT01864317 Phase 2
34 Effect of Noninvasive Neuromodulation on Chronic Pain Recruiting NCT03285685 Phase 2
35 Transcranial Direct Current Simulation in Chronic Migraine Recruiting NCT02817139 Phase 1, Phase 2
36 The Effects of Repetitive Transcranial Magnetic Stimulation in Obese People With BED Recruiting NCT02180984 Phase 2
37 Effects of Erythropoietin on Cognition and Neural Activity in Bipolar Disorder Recruiting NCT03315897 Phase 2 Erythropoietin;Saline
38 Nitrous Oxide as a Putative Novel Dual-Mechanism Treatment for Bipolar Disorder Recruiting NCT02351869 Phase 2 Nitrous Oxide;Midazolam
39 Bilateral Prefrontal Modulation in Alcoholism Recruiting NCT02091284 Phase 2
40 Bilateral Prefrontal Modulation in Crack-cocaine Addiction Recruiting NCT02091167 Phase 2
41 Effects of Transcranial Direct Current Stimulation (tDCS) on Patients With Chronic Orofacial Pain Terminated NCT01883245 Phase 2
42 Deep Low-Frequency Repetitive Transcranial Magnetic Stimulation for Cessation of Pathological Gambling Unknown status NCT01154712 Phase 1
43 Near-infrared Light (NIR) Therapy for Diabetic Macular Edema: A Pilot Study Completed NCT00846092 Phase 1
44 Visual Cortex Stimulation in Patients With Amblyopia Completed NCT00097162 Phase 1
45 Effects of GABA Modulator AZD7325 on Cortical Excitability Completed NCT02135198 Phase 1 2 mg AZD7325;10 mg AZD7325;Placebo
46 PET Imaging Study of Amish and Mennonite Patients With CNTNAP2 Mutations Terminated NCT02572206 Phase 1
47 Neuromodulation on Motor Function in Parkinson's Disease Unknown status NCT02250690
48 Retinal Function in Parkinson's Disease Unknown status NCT01010074
49 a 3.0T Magnetic Resonance Imaging Study Unknown status NCT01346904
50 Inhibitory rTMS in Dystonic Wilson Patients Unknown status NCT01980433

Search NIH Clinical Center for Visual Cortex Disease

Genetic Tests for Visual Cortex Disease

Anatomical Context for Visual Cortex Disease

MalaCards organs/tissues related to Visual Cortex Disease:

Cortex, Brain, Eye, Testes, Cingulate Cortex, Prefrontal Cortex, Amygdala

Publications for Visual Cortex Disease

Variations for Visual Cortex Disease

Expression for Visual Cortex Disease

Search GEO for disease gene expression data for Visual Cortex Disease.

Pathways for Visual Cortex Disease

GO Terms for Visual Cortex Disease

Biological processes related to Visual Cortex Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cholesterol metabolic process GO:0008203 9.16 CLN6 CLN8
2 protein catabolic process GO:0030163 8.96 CLN6 CLN8
3 lysosome organization GO:0007040 8.62 CLN6 MFSD8

Sources for Visual Cortex Disease

9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
32 HPO
33 ICD10
34 ICD10 via Orphanet
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
52 Novoseek
55 OMIM via Orphanet
59 PubMed
66 SNOMED-CT via Orphanet
68 Tocris
70 UMLS via Orphanet
Loading form....